ESC 2022: Bayer, like its rivals, hopes it made a big
enough splash after phase 2 belly flop
Bayer's
anticoagulant to prevent secondary strokes flopped a phase 2 trial, keeping in
line with results from rivals BMS and J&J. The company reported that its
med, asundexian, did not produce a dose-dependent reduction in the composite
rate of covert brain infarction or ischemic stroke.
No comments:
Post a Comment